Tempest Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated March 29, 2022, reports the financial results for Tempest Therapeutics, Inc. for the fiscal year ended December 31, 2021. The filing incorporates by reference a press release titled "Tempest Reports Year End 2021 Financial Results and Provides Corporate Highlights."
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing serves as a notification that these results were announced via a press release (Exhibit 99.1), but the detailed financial data is not included in the body of this document.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in this filing text. The document states that the information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 29, 2022) for actual financial figures.
- Verify the specific revenue and net loss figures for the year ended December 31, 2021.
- Check the cash position and burn rate disclosed in the full press release.
- Confirm any updates to the company's clinical pipeline or corporate highlights mentioned in the referenced exhibit.